Table of Contents

1 Study Coverage

• 1.1 Erythropoietin Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Erythropoietin Market Size Growth Rate by Product
  • 1.4.2 Epoetin-alfa
  • 1.4.3 Epoetin-beta
  • 1.4.4 Darbepoetin-alfa
  • 1.4.5 Others
• 1.5 Market by End User
  • 1.5.1 Global Erythropoietin Market Size Growth Rate by End User
  • 1.5.2 Anemia
  • 1.5.3 Kidney Disorders
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Erythropoietin Market Size
  • 2.1.1 Global Erythropoietin Revenue 2014-2025
  • 2.1.2 Global Erythropoietin Sales 2014-2025
• 2.2 Erythropoietin Growth Rate by Regions
  • 2.2.1 Global Erythropoietin Sales by Regions
  • 2.2.2 Global Erythropoietin Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Erythropoietin Sales by Manufacturers
  • 3.1.1 Erythropoietin Sales by Manufacturers
  • 3.1.2 Erythropoietin Sales Market Share by Manufacturers
  • 3.1.3 Global Erythropoietin Market Concentration Ratio (CR5 and HHI)
• 3.2 Erythropoietin Revenue by Manufacturers
  • 3.2.1 Erythropoietin Revenue by Manufacturers (2014-2019)
  • 3.2.2 Erythropoietin Revenue Share by Manufacturers (2014-2019)
• 3.3 Erythropoietin Price by Manufacturers
• 3.4 Erythropoietin Manufacturing Base Distribution, Product Types
  • 3.4.1 Erythropoietin Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Erythropoietin Product Type
  • 3.4.3 Date of International Manufacturers Enter into Erythropoietin Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Erythropoietin Sales by Product
• 4.2 Global Erythropoietin Revenue by Product
• 4.3 Erythropoietin Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Erythropoietin Breakdown Data by End User

6 North America

• 6.1 North America Erythropoietin by Countries
  • 6.1.1 North America Erythropoietin Sales by Countries
  • 6.1.2 North America Erythropoietin Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Erythropoietin by Product
• 6.3 North America Erythropoietin by End User

7 Europe

• 7.1 Europe Erythropoietin by Countries
  • 7.1.1 Europe Erythropoietin Sales by Countries
  • 7.1.2 Europe Erythropoietin Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Erythropoietin by Product
• 7.3 Europe Erythropoietin by End User

8 Asia Pacific

• 8.1 Asia Pacific Erythropoietin by Countries
  • 8.1.1 Asia Pacific Erythropoietin Sales by Countries
  • 8.1.2 Asia Pacific Erythropoietin Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Erythropoietin by Product
• 8.3 Asia Pacific Erythropoietin by End User

9 Central & South America

• 9.1 Central & South America Erythropoietin by Countries
  • 9.1.1 Central & South America Erythropoietin Sales by Countries
  • 9.1.2 Central & South America Erythropoietin Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Erythropoietin by Product
• 9.3 Central & South America Erythropoietin by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Erythropoietin by Countries
  • 10.1.1 Middle East and Africa Erythropoietin Sales by Countries
  • 10.1.2 Middle East and Africa Erythropoietin Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Erythropoietin by Product
• 10.3 Middle East and Africa Erythropoietin by End User

11 Company Profiles

• 11.1 Amgen
  • 11.1.1 Amgen Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Amgen Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Amgen Erythropoietin Products Offered
  • 11.1.5 Amgen Recent Development
• 11.2 Johnson & Johnson
  • 11.2.1 Johnson & Johnson Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Johnson & Johnson Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Johnson & Johnson Erythropoietin Products Offered
  • 11.2.5 Johnson & Johnson Recent Development
• 11.3 Roche
  • 11.3.1 Roche Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Roche Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Roche Erythropoietin Products Offered
  • 11.3.5 Roche Recent Development
• 11.4 Galenica
  • 11.4.1 Galenica Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Galenica Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Galenica Erythropoietin Products Offered
  • 11.4.5 Galenica Recent Development
• 11.5 Emcure
  • 11.5.1 Emcure Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Emcure Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Emcure Erythropoietin Products Offered
  • 11.5.5 Emcure Recent Development
• 11.6 Kyowa Hakko Kirin
  • 11.6.1 Kyowa Hakko Kirin Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Kyowa Hakko Kirin Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Kyowa Hakko Kirin Erythropoietin Products Offered
  • 11.6.5 Kyowa Hakko Kirin Recent Development
• 11.7 3SBio
  • 11.7.1 3SBio Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 3SBio Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 3SBio Erythropoietin Products Offered
  • 11.7.5 3SBio Recent Development
• 11.8 Biocon
  • 11.8.1 Biocon Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Biocon Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Biocon Erythropoietin Products Offered
  • 11.8.5 Biocon Recent Development
• 11.9 LG Life Sciences
  • 11.9.1 LG Life Sciences Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 LG Life Sciences Erythropoietin Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 LG Life Sciences Erythropoietin Products Offered
  • 11.9.5 LG Life Sciences Recent Development

12 Future Forecast

• 12.1 Erythropoietin Market Forecast by Regions
  • 12.1.1 Global Erythropoietin Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Erythropoietin Revenue Forecast by Regions 2019-2025
• 12.2 Erythropoietin Market Forecast by Product
  • 12.2.1 Global Erythropoietin Sales Forecast by Product 2019-2025
  • 12.2.2 Global Erythropoietin Revenue Forecast by Product 2019-2025
• 12.3 Erythropoietin Market Forecast by End User
• 12.4 North America Erythropoietin Forecast
• 12.5 Europe Erythropoietin Forecast
• 12.6 Asia Pacific Erythropoietin Forecast
• 12.7 Central & South America Erythropoietin Forecast
• 12.8 Middle East and Africa Erythropoietin Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Erythropoietin Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.

In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml

The classification of erythropoietin includes epoetin-alfa, epoetin-beta, darbepoetin-alfa and others. The proportion of epoetin-alfa in 2016 is about 58.53%.
Erythropoietin is widely used for anemia and kidney disorders. The most proportion of Erythropoietin used in Kidney Disorders, and the market share in 2016 is 45.91%.
The global Erythropoietin market is valued at 7240 million US$ in 2018 and will reach 10700 million US$ by the end of 2025, growing at a CAGR of 5.8% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Erythropoietin market based on company, product type, end user and key regions.

This report studies the global market size of Erythropoietin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Erythropoietin in these regions.
This research report categorizes the global Erythropoietin market by top players/brands, region, type and end user. This report also studies the global Erythropoietin market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences

Market size by Product
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Market size by End User
Anemia
Kidney Disorders
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Erythropoietin market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Erythropoietin market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Erythropoietin companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Erythropoietin submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Erythropoietin are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (M Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Erythropoietin market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.